Presseinformationen

Krebs betrifft nicht nur den Körper, sondern das ganze Leben.

DATROWAY® Demonstrated an Unprecedented Median Overall Survival Improvement of Five Months Versus Chemotherapy as First- line Treatment for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option...

Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial

ENHERTU® Reduced the Risk of Disease Recurrence or Death by 53% Versus T-DM1 in Patients with High-Risk HER2 Positive Early Breast Cancer Following Neoadjuvant Therapy in DESTINY- Breast05 Phase 3 Trial

ENHERTU® Followed by THP Before Surgery Resulted in a Pathologic Complete Response in 67% of Patients with High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial

DATROWAY® Plus Rilvegostomig Showed Promising Tumor Responses in Patients with Metastatic Urothelial Cancer in TROPION-PanTumor03 Phase 2 Trial

Phase-III-Studie HERTHENA-Lung02

Neues vom ESMO: Trastuzumab deruxtecan zeigt bedeutsame klinische Aktivität bei Patient:innen mit metastasiertem HER2-positivem Mammakarzinom und Hirnmetastasen

Datopotamab deruxtecan zeigte in der Phase-III-Studie TROPION-Lung01 ein medianes Gesamtüberleben von 14,6 Monaten bei Patient:innen mit fortgeschrittenem nicht-plattenepithelialem NSCLC

ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial